

innovotech

Corporate Presentation


(TSX-V:IOT)

A PROFITABLE REVENUE PLATFORM
A GROWING ASSET PLATFORM
A TAX PROTECTED PLATFORM

THE BASE ON WHICH WE BUILD

Our plan is to use **time, effort, discipline**, and
innovation to deliver a diversified Canadian Biotech.

Brief History




Our Business 1: Contract Research Organization

Innovotech is a CRO. The Company is a leader in contract research testing of coated medical devices like implants for their susceptibility or resistance to the formation of microbial biofilms that cause chronic infections and disease in humans.

- Innovotech has long experience that provides proprietary advantages and efficiencies
- In early 2019 ISO 17025 certification opened doors with new and existing clients
- The Company innovates. Our patented “BESTplus Assay™” system brings *in vitro* closer to *in vivo*, raising our contract research profile
- In 2020, we begin to use 3D printers to build test devices tailored to accommodate shapes, formats, and materials of customer devices. We are creative
- In September 2020, Innovotech recorded 100,000 hours of laboratory work without a single lost time incident
- Innovotech’s contract research has become materially profitable. The Company’s revenues have increased from \$826,935 in the 2018 year to \$1,481,767 in 2021

5 Year Trend: Revenue & Net Income



Our Business 2: MBEC Assay® Kits & InnovoSIL™-1 Silver

● MBEC ASSAY® KITS

Innovotech makes and sells globally the MBEC Assay® Kits, a high throughput biofilm growth device. Any hard surface or disinfectant claiming effectiveness against biofilms must pass ASTM tests based on the Innovotech MBEC Assay® growth device.

● INNOVOSIL™-1 SILVER

July 2020: Innovotech signed a Collaboration Agreement with a medical device partner on our complex silver periodate, InnovoSIL™-1 antimicrobial, aimed at a potential commercial agreement.


January 2022: the medical device company elected to terminate the Collaboration Agreement for reasons unrelated to the anti-microbial effectiveness of the InnovoSIL™-1 antimicrobial.

Innovotech continues to work with other collaborators under material transfer and feasibility agreements.

A **profitable**, listed Canadian micro-cap biotech...

- In the twelve months to December 31st, 2021 Innovotech earned a profit of \$367,130, or 1¢ per share. As noted, \$85,995 of the 2021 profit was derived from an increase in the fair value of the Company's CanBiocin debenture, which was converted into 120,000 CanBiocin shares on April 14th, 2022.
- The increase in the fair market value of the debenture at yearend, 2021 was based on CanBiocin having increased its revenues by 300% in the 2021 year and having completed a financing at \$1.75 per share. This is the price that Innovotech has determined to be fair value for the shares into which the debenture has now been converted. The Company is optimistic in regard to the future potential of this investment, which it acquired in exchange for 625,000 Innovotech treasury shares at a deemed value of \$0.24 in Q1 of 2021.
- The effect of the improved 2021 Company financial performance resulted in working capital of \$774,521. The profitability, combined with the “for shares” acquisition of the CanBiocin debenture resulted in an increase in shareholder's equity from \$644,978 to \$1,176,930.

5 Year Trend: Shareholder's Equity



Recent Corporate Developments in R&D and Diversification

Tangible Progress

Innovotech has used increasing profits, its strong balance sheet and treasury shares to diversify and to participate in products that may be applicable to consumer markets.

- **Q1 2021: investment acquisition, -Nou Life Sciences Inc.**

In skin care, Innovotech acquired the right in January, 2021 to earn a 60% interest in Nou Life Sciences for \$100,000 invested over 2 years in R&D. Nou Life's asset is a patent linking two well-known anti-oxidants into one molecule. Once linked, the Company will test the ability of the linked molecules to better penetrate subdermally to perform their anti-oxidant function. The terms of this investment transaction reduce the inherent risk in developing new technology.

- **Q1 2021: investment acquisition, -CanBiocin Inc.**

In probiotics, Innovotech now holds equity in a rapidly growing company with multiple lines of companion animal and farm animal probiotics sold across North America and globally. We are optimistic about CanBiocin's future growth.

The Company intends to continue to acquire and diversify its biotech interests under its “partial acquisition” investment program, outlined below.

External Growth Plan: **Investment**

Growth through investment – partial company acquisition

Innovotech is interested in right-sized investment opportunities such as the described probiotics and skin cream acquisitions to extend our reach, diversify our assets and open avenues to larger markets even if it is through indirect equity participation.

- For Innovotech to grow and diversify year-over-year, we see that it is generally easier, cheaper, faster, and less dilutive at the Company's current stage of development to own a piece of an attractive company, product, or service than to necessarily try to own it all
- Investment acquisition targets are biotech and human health related: microbiology, pharmaceuticals, nutraceuticals, probiotics etc. Targets require a record of past performance and a visible route toward a risked long-term ROI for the Company. The convertible debenture route is a favoured route where possible
- This plan is not designed to acquire held-for-sale trading assets. The plan is a way for Innovotech to access long-term affordable investment opportunities in the field of human health in a manner complimentary to the Company's growing contract research revenues.

Internal Lean Growth Plan

Organic growth (2022)

- Innovotech continues to work to add new accounts to our growing business and was successful at that in 2021.
- We continue to work up devices and products to separate us from our competition and improve the quality and efficiency of our testing of client medical devices
- We seek to monitor and control our general and administrative costs against a growing business
- The Company has increased its staff and facilities in response to increased business
- We have a plan to re-establish product-focused R&D as an operating component of the business in a measured manner levered by government grants where possible

Research and Development (2022)

- InnovoSIL™-1 silver is a highly effective antimicrobial coating. The Company is continuing R & D toward developing new applications for antimicrobial silver compounds
- R&D continues on the Nou Life linked Lipoic Acid and L- carnitine anti-oxidant molecules to target a 2 to 3 times increase in skin penetration over existing industry products

External Growth Plan: Acquisition

Whole company acquisition

● The tax case

Prior year's NOLs and SRED tax credits provide a long-term tax pool of \$7.2 million (Dec. 31, 2021) available to reduce our future net income for tax purposes. The pools can do the same for an acquired company. These pools do not start to expire until 2028; \$3.5 million worth never expire. Therefore, we look for profitable acquisition candidates that can make use of the tax pools.


● The appeal

Innovotech is one of few micro-cap, listed, Canadian biotech companies that has revenue business base, profitability, and a strong balance sheet. This, together with its tax pools, makes us a top M&A candidate. We are not pressed to do a deal. We only plan to get stronger over time.

● In the meantime

We continue with our successful lean Internal growth plan and “partial company acquisition plan” as we seek a larger acquisition partner targeting increased revenue and profitability.

2 Year trend: Quarterly Revenue & Net Income



● Officers & Management

Dr. James Timourian	President
Alan Savage	CFO
Dr. Tyler Boone	COO
Dr. Patricia Nadworny	CSO

● Directors

Dr. James Timourian, PhD*

Alan Savage*

Dr. Gerard Tertzakian, PhD

David Tam, BSc. Pharma, LLB

Dr. Craig Milne, PhD, MBA

Bernard Grobbelaar CPA

Dr. Karen Farkas PhD

*Members of the Executive Committee

Mission & Vision of Innovotech

Scale up Innovotech to be a significant, innovative, profitable participant in the Canadian biotech sector

- The time frame for the mission is not a short one. Innovotech has a knowledgeable, committed, invested and incentivized Board. It has a major shareholder and management with the experience, expertise and desire to succeed
- The vision is supported by our pristine balance sheet, our usable long-term tax pools, rising revenues, and profitability
- In terms of growth through acquisition, one day, one of those acquisitions will be a larger one

- **Share Capital**

Authorized Unlimited

Issued 38,909,612

Directors hold as of AGM, October 12, 2021:

James Timourian 2,085,812

Gerry Tertzakian 1,041,998

Craig Milne 160,000

Karen Farkas 15,000

Bernard Grobbelaar 65,000

David Tam 592,000

Alan Savage (through Lonsdale Capital) 13,180,500

- **Warrants** (exercisable @ \$0.25 until 09/02/23) 1,875,000

- **Stock Options** 1,825,000



Disclaimer

This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company's reliance on a small number of customers including government organizations; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; the Company's exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should management's assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward-looking statements, except as required by applicable law.